FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden

0.5

hours per response:

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A	Address of Rep	orting Person [*]	2. Date of Event Requiring Statement (Month/Day/Year) 03/31/2022 3. Issuer Name and Ticker or Trading Symbol Reneo Pharmaceuticals, Inc. [RPHM]							
(Last) (First) (Middle) C/O RENEO PHARMACEUTICALS, INC.					Relationship of Reporting Issuer (Check all applicable) Director	10% Owner Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year)		
18575 JAMBOREE ROAD, SUITE 275-S					X Officer (give title below) VP of Finance & Ac			(Ch	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person	
(Street) IRVINE								Form filed by More than One Reporting Person		
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)				- 1	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Owner Form: D (D) or In (I) (Instr	Direct Own ndirect		lature of Indirect Beneficial nership (Instr. 5)	
Common Stock					15,000	I D	D			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
Expir			2. Date Exerc Expiration Day/\ (Month/Day/\	ate	3. Title and Amount of Securitie Underlying Derivative Security (Instr. 4)		4. Conver	sion cise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr.
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security		or Indirect (I) (Instr. 5)	5)
Stock Option	n (right to bu	ıy)	(1)	09/09/2031	Common Stock	50,000	8.66		D	
Stock Option	n (right to bu	ıy)	(2)	12/09/2031	Common Stock	35,000	6.69		D	
Stock Option	n (right to bu	ıy)	(3)	03/01/2032	Common Stock	10,000	4.58		D	

Explanation of Responses:

- 1. 1/4 of the shares vest and become exercisable on September 10, 2022, and the remaining shares vest in equal monthly installments over the subsequent 36 months, subject to Reporting Person's Continuous Service (as defined in the 2021 Equity Incentive Plan) as of each such vesting date.
- 2. The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the 2021 Equity Incentive Plan) as of each such vesting date.
- 3. The shares vest in a series of 48 successive equal monthly installments measured from March 2, 2022, subject to Reporting Person's Continuous Service (as defined in the 2021 Equity Incentive Plan) as of each such vesting date.

Remarks:

<u>/s/ Jennifer Lam</u> <u>04/05/2022</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Gregory J. Flesher and Michael Cruse of Reneo Pharmaceuticals, Inc. (the Company), signing individually, the undersigned's true and lawful attorney-in fact and agent to:

- (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act) and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-facts discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-facts substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of March 18, 2022.

/s/ Jennifer Lam Jennifer Lam